Patents by Inventor Jean-Marc Balloul
Jean-Marc Balloul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9024003Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: GrantFiled: January 5, 2007Date of Patent: May 5, 2015Assignee: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8932599Abstract: The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.Type: GrantFiled: September 10, 2009Date of Patent: January 13, 2015Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Paris Est Creteil Val de MarneInventors: Yves Levy, Jean-Marc Balloul, Doris Schmitt, Caterina Riconda Guillet
-
Patent number: 8778675Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: GrantFiled: February 25, 2013Date of Patent: July 15, 2014Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Publication number: 20130236929Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: February 25, 2013Publication date: September 12, 2013Applicant: TRANSGENE S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Patent number: 8445270Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: GrantFiled: May 11, 2010Date of Patent: May 21, 2013Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Patent number: 8420103Abstract: A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3? portion of the first nucleotide which in the natural content is 100% identical to the 5? portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.Type: GrantFiled: January 29, 2008Date of Patent: April 16, 2013Assignee: Transgene S.A.Inventors: Martine Baudin, Jean-Marc Balloul, Nathalie Silvestre
-
Publication number: 20120122155Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: May 17, 2012Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY
-
Publication number: 20110212488Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (W—COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxyiridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: May 11, 2010Publication date: September 1, 2011Applicant: TRANSGENE S.A.Inventors: Jean-Marc BALLOUL, Marina KAPFER, Thierry MENGUY
-
Publication number: 20110171250Abstract: The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.Type: ApplicationFiled: September 10, 2009Publication date: July 14, 2011Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MInventors: Jean-Gérard Guillet, Caterina- Riconda Guillet, Yves Levy, Jean-Marc Balloul, Doris Schmitt
-
Publication number: 20100173378Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: ApplicationFiled: January 5, 2007Publication date: July 8, 2010Applicant: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20100143408Abstract: A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3? portion of the first nucleotide which in the natural content is 100% identical to the 5? portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.Type: ApplicationFiled: January 29, 2008Publication date: June 10, 2010Inventors: Martine Baudin, Jean-Marc Balloul, Nathalie Silvestre
-
Patent number: 7670607Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumor, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.Type: GrantFiled: December 8, 2008Date of Patent: March 2, 2010Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
-
Publication number: 20090104156Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.Type: ApplicationFiled: December 8, 2008Publication date: April 23, 2009Applicant: Transgene S.A.Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
-
Patent number: 7488482Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.Type: GrantFiled: September 18, 2006Date of Patent: February 10, 2009Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
-
Patent number: 7354591Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.Type: GrantFiled: April 12, 2001Date of Patent: April 8, 2008Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Stéphane Paul, Michel Geist
-
Patent number: 7348014Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.Type: GrantFiled: September 7, 2004Date of Patent: March 25, 2008Assignee: Transgene, S.A.Inventors: Jean Marc Balloul, Stephane Paul, Michel Geist, Nathalle Silvestre, Philippe Erbs
-
Patent number: 7332478Abstract: Antitumoral compositions can comprise as therapeutic agent one or several immunogenic polypeptides, of which at least one is modified so as to have a cell location different from its native location. Compositions can be based on a recombinant vector expressing such an immunogenic polypeptide. A recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from a precocious and/or tardive region of a papillomavirus having a modified location and a viral particle comprising said vector is also described. Finally, therapeutic uses of such a composition, such a recombinant vector and such a viral particle are described.Type: GrantFiled: March 7, 2005Date of Patent: February 19, 2008Assignee: TransgeneInventors: Marie-Paule Kieny, Jean-Marc Balloul, Nadine Bizouarne
-
Publication number: 20070065459Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.Type: ApplicationFiled: September 18, 2006Publication date: March 22, 2007Applicant: Transgene S.A.Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
-
Patent number: 7118754Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.Type: GrantFiled: February 18, 2000Date of Patent: October 10, 2006Assignee: Transgene S.A.Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
-
Publication number: 20050245471Abstract: The invention concerns combination products comprising (i) at least a substance capable of inhibiting CSF-1 activity and/or at least a nucleic acid, comprising at least a sequence coding for a substance capable of inhibiting CSF-1 activity and (ii) at least a substance having a cytotoxic activity and/or at least a nucleic acid, comprising at least a sequence coding for a substance having cytotoxic activity. The invention also concerns oligonucleotides capable of inhibiting CSF-1 expression. The invention is particular useful for implementing an antitumoral treatment.Type: ApplicationFiled: January 3, 2003Publication date: November 3, 2005Inventors: Jean-Marc Balloul, Suzy Scholl, Jerome Lacoste